Korro Bio, Inc. (KRRO)

Market Cap	154.61M +1.8%
Revenue (ttm)	3.84M -20.3%
Net Income	-113.50M
EPS	-11.41
Shares Out	14.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,667
Open	11.09
Previous Close	11.18
Day's Range	10.46 - 11.28
52-Week Range	5.20 - 55.89
Beta	2.10
Analysts	Strong Buy
Price Target	20.00 (+86.57%)
Earnings Date	May 7, 2026

About Hatton National Bank

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: KRRO
• Website: https://www.korrobio.com

Financial Performance

In 2025, Korro Bio's revenue was $6.39 million, an increase of 181.46% compared to the previous year's $2.27 million. Losses were -$117.26 million, 40.3% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 86.57% from the latest price.

Price Target

$20.0

(86.57% upside)

Analyst Consensus: Strong Buy